Drug class | Drug | Dose | Study (phase) | Studytimec | Population | N | Age criteria | Agea | Primary outcome/endpoint | Main conclusion |
---|---|---|---|---|---|---|---|---|---|---|
IL-12/23 inhibitor | ustekinumab | 0.75 mg/kg, 22.5/45/ 90 mg | dCADMUS, NCT01090427 (III) [93]b | 60 | Plaque psoriasis | 110 | 12 to 17 | 15.2 | PGA ≤1 | Effective |
IL-17 inhibitor | ixekizumab | 20 mg BW < 25 kg q4w, 40 mg BW 25–50 kg q4w, 80 mg BW > 50 kg q4w | eIXORA-PEDS, NCT03073200 (III) [94] b | 12 | Plaque psoriasis | 201 | 6 to 17 | 13.5 | PASI75, PGA ≤1 | Effective |
TNF inhibitor | adalimumab | 0.4 mg/kg q2w, 0.8 mg/kg q2w | fM04–717, NCT01251614 | 52 | Plaque psoriasis | 114 | 4 to 17 | 13 | PASI75, PGA ≤1 | Effective |
etanercept | 0.8 mg/kg/qw | EATAK, NCT00841789 (II) [99] b | 6 | KD | 205 | 0 to 18 | 3.7 | Fever | Not effective | |
0.8 mg/kg/qw | 20030211, NCT00078819 | 48 | Plaque psoriasis | 211 | 4 to 17 | 13a | PASI75 | Effective | ||
infliximab | 5 mg/kg single dose | Han 2018 (NA) [105] b | 0.571 | KD | 154 | 0 to 4 | 2.2a | Unclear | Effective | |
5 mg/kg single dose | TA-650-22, NCT01596335 (III) [106] b | 8 | KD | 31 | 1 to 10 | 3a | Defervescence | Effective | ||
5 mg/kg single dose | 5 | KD | 196 | 0 to 17 | 3a | Fever | Effective | |||
5 mg/kg, 10 mg/kg q4w | Pro00000057, NCT00589628 (IV) [109] b | 39 | Non-infectious uveitis | 13 | 4 to 18 | NA | Uveitis disease activity | NA | ||
BAFF inhibitor | belimumab | 10 mg/kg qm | gPLUTO, NCT01649765 | 52 | SLE | 93 | 5 to 17 | 14 | SRI4 | Effective |